Current Concepts in Allogeneic Hematopoietic Stem Cell Transplantation

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5055-5067

  Tabbara, Imad A ^a,c   Kairouz, Sebastien ^b   Nahleh, Zeina ^a   Mihalcea, Ana Maria ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Review

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; DIURETIC AGENT; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; SARCOLYSIN; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; APLASTIC ANEMIA; BONE MARROW APLASIA; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLONY FORMING UNIT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; COST CONTROL; DIARRHEA; DIURESIS; DONOR; ERADICATION THERAPY; GENERAL ANESTHESIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMORRHAGIC CYSTITIS; HLA TYPING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; STEM CELL; UMBILICAL CORD BLOOD; VOMITING; WHOLE BODY RADIATION;

GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0842278697     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Bodmer WF, Albert E, Bodmer JG, Marsh SG, Dupont B. Erlich HA, Mach B. Mayr WR, Parham P and Sasazuki T: Nomenclature for factors of the HLA system 1987 Immunobiology of HLA, Vol 1. Histocompatibility Testing 1987. Dupont B (ed.). New York, Springer-Verlag, 1991, pp 72-79.
2. Sullivan KA and Amos DB: The HLA system and its detection. Manual of Clinical Laboratory Immunology. Rose NR, Friedman H, Fahey JL (eds), Washington, D.C., American Society for Microbiology, 3rd Ed, 1986, pp 835-846.
3. Noreen H, Yu N, Setterholm M, Ohasi M, Baisch J, Endres M, Fernandez-Vina M, Heine U, Hsu S, Kamoun M, Mitsuishi Y, Monos D, Perlee L, Rodriguez-Marino S et al: Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology. Tissue Antigens 57, 3: 221, 2001.
4. Hansen JA, Mickelson EM, Beatty PG et al: Clinical bone marrow transplantation: Donor selection and recipient monitoring. Manual of Clinical Laboratory Immunology. Rose NR, Friedman H, Fahey JL (eds), Washington, D.C., American Society for Microbiology, 3rd Ed, 1986, pp 892-901.
5. Thomsen M, Alvarez C and Carpenter CB: Analysis of HLA recombinant families by Southern blots. Immunobiology of HLA, Vol 1. Histocompatibility Testing 1987. Dupont B (ed.) New York, Springer-Verglag, 1989, pp 900-908.
6. Petersdorf EW, Smith AG, Mickelson EM, Martin PJ and Hansen JA: The HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain. Immunogenetics 33: 267-275, 1991.
7. Lanchbury JS, Jaeger EE, Welsh KI and Panayi GS: Nucleotide sequence of a novel HLA-DRB4B1 allele, DRB1*0409. Immunogenetics 33: 210-212, 1991.
8. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, Ishikawa Y, Kato S, Sao H, Sakamaki H, Kawa K, Hamajima N, Asano S and Kodera Y: The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B and HLA-DR matched unrelated donors: Blood 99: 4200-4206, 2002.
9. Petersdorf E, Kollman C, Hurley C, Nademanee A, Begovich A, Weisdorf D and McGlave P: effect of HLA class 2 gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98: 2922-2929, 2001.
10. Gallardo D, Arostegui J, Balas A, Torres A, Caballero D, Carreras E, Brunet S, Jiminez A, Mataix R, Serrano D, Vallejo C, Sanz G, Rodriguez-Luaces M, Marin J, Baro J et al: Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GVHD) but it does not affect chronic GVHD incidence, disease-free survival or overall survival after allogeneic human leukocyte antigen-identical sibling donor transplantation. Br J Hematol 114: 931-936, 2001.
11. Beatty PG, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin PJ and Hansen JA: Probability of finding HLA-matched unrelated marrow donors. Transplantation 45: 714-718, 1988.
12. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J and McCullough J: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328: 593-602, 1993.
13. Marks DI, Cullis JO, Ward KN, Lacey S, Syzdlo R, Hughes TP, Schwarer AP, Lutz E, Barrett AJ and Hows JM: Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first 2 years. Ann Intern Med 119: 207-214, 1993.
14. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R and Cosset JM: Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood 78: 2451-2455.
15. Champlin RE, Ho WG, Nimer SD, Gajewski JG, Selch M, Burnison M, Holley G, Yam P, Petz L and Winston DJ: Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose-total lymphoid irradiation and post-transplant cyclosporine-methotrexate therapy. Transplantation 49: 720-724, 1990.
16. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA and Rozman C: Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 73: 606-613, 1989.
17. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, Bryant E, Clift R, Deeg HJ and Doney K: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84: 941-949, 1994.
18. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD and Hansen JA: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84: 2036-2043, 1994.
19. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M and Ifrah N: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfancytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la greffe de Moelle osseuse. Blood 79: 2578-2582, 1992.
20. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Mellander L, Ljungman P and Jacobsen N: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic bone marrow transplant in recipients with leukemia - a report from the Nordic Bone Marrow Transplantation Group. Blood 83: 2723-2730, 1994.
21. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, Bordigoni P, Ifrah N, Dauriac C and Cahn JY: Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85: 2263-2268, 1995.
22. Socie G, Reginald C, Blaise D, Devergie A, Ringden O, Martin P, Remberger M, Deeg H, Ruutu T, Michallet M, Sullivan K and Chevret S: Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98: 3569-3574, 2001.
23. Deeg J, Storer B, Slattery T, Anasetti C, Doney K, Kiem H, Martin P, Petersdorf E, Radich J, Sanders J, Shulman H, Warren E, Witherspoon R, Bruant E, Chauncey T, Getzendaner L, Storb R and Appelbaum F: Conditioning with targeted busulfan and cyclophosphamide for hemopoetic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100: 1201-1207, 2002.
24. 2 mephalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99: 731-735, 2002.
25. Clift RA, Buckner CD, Appelbaum FR et al: Allogeneic marrow transplantation with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76: 1867-1871, 1990.
26. Clift RA, Buckner CD, Appelbaum FR et al: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase: a randomized trial of two irradiation regimens. Blood 77: 1660-1665, 1991.
27. Kotzerke J, Glatting G, Seitz V, Rentschler M, Neumaier B, Bunjes D, Dunker C, Dohr D, Bergmann L and Reske S: Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188 Re-and 99m Tc-labeled anti-NCA-9S MAbs. J Intern Med 41: 531-537, 2000.
28. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K et al: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9(3): 478-490, 1991.
29. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54(5): 829-833, 1992.
30. Matthews DC, Badger CC, Fisher DR, Hui TE, Nourigat C, Appelbaum FR et al: Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res 52(5): 1228-1234, 1992.
31. Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ et al: Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 34(6): 908-917, 1993.
32. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR et al: Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11(2): 294-303, 1993.
33. Griffiths GL, Goldenberg DM, Diril H and Hansen HJ: Technetium-99m, rhenium-186 and rhenium-188 direct-labeled antibodies. Cancer 73(3 Suppl): 761-768, 1994.
34. Knapp FF Jr, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo H et al: Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 17(3B): 1783-1795, 1997.
35. 6 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26: 489-496, 2000.
36. Lefere F, Delarue R, Somme D, Levy V, Damaj G, Tu A, Porcher R, Audat F, Boulat C, Cavazzana-Calvo M et al: High dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion 42: 443-450, 2002.
37. Podesta M: Transplantation hematopoesis. Curr Opin Hematlol 8: 331-336, 2001.
38. Demirer T, Ilhan O, Arat M, Genc Y, Ozcan M, Dalva K, Celebi H, Beksac M, Akan H, Gurman G, Konuk N, Uysal A, Arslan O and Koc H: CD41+ and CD42+ hematopoetic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation. J Clin Apheresis 16: 67-73, 2001.
39. Sumikuma T, Shimazaki C, Inaba T, Ochiai N, Okano A, Hatsuse M, Ashihara E and Nakagawa M: CD34+/CD90+ cells infused best predict late hematopoetic reconstitution following autologous peripheral stem cell transplantation. Br J Hematol 117: 238-244, 2002.
40. Basara N, Schmetzer B, Blau I, Bischoff M, Guenzelmann S, Kirsten D and Fauser A: Lenograstim-mobilized peripheral blood progenitor cells in colunteer donors: an open label randomized split dose escalating study. Bone Marrow Transplant 25: 371-376, 2000.
41. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85: 1659-65, 1995.
42. Bensinger WI, Weaver CH, Appelbaum FR, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers ME, Lilleby K, Chauncey TR, Storb R and Appelbaum FR: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 85: 1655-1658, 1995.
43. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A and Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood 85: 1666-1672, 1995.
44. Goldman J: Peripheral blood stem cells for allografting. Blood 85(6): 1413-1415, 1995.
45. Lapierre V, Auperin A, Tayelin H et al: Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. Blood 100: 1484-1489, 2002.
46. Bensinger W, Martin P, Storer B et al: Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344: 17-181, 2001.
47. Couban S, Simpson D, Barnett M, Bredeson C, Hubesch L, Howson-Jan K, Messner H, Panzarella T and Lipton J: A randomized multicentre comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100: 1525-1531, 2002.
48. Flowers M, Parker P, Johnston L, Matos A, Storer B, Bensinger W, Storb R, Appelbaum F, Forman S, Blume K and Martin P: Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100: 415-419, 2002.
49. Cutler C, Giri S, Paniagua D, Viswanathan A and Antin J: Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 19: 3685-3691, 2001.
50. Ringden O, Lonnquist B, Hagglund H, Ljungman P, Shanwell A, Lawlor E et al: Transplantation with peripheral blood stem cells from unrelated donors without serious graft versus host disease (letter). Bone Marrow Transplant 16: 856-7, 1995.
51. Stockschlader M, Loliger C, Kruger W, Zeller W, Heyll A, Schonrock-Nabulsi P et al: Transplantatation of allogeneic rhG-CSF mobilized peripheral CD34 + cells from a HLA-identical unrelated donor. Bone Marrow Transplant 16(5): 719-22, 1995.
52. Ringden O, Hapgglund H, Runde V, Ljungman P, Shanwell A, Lawlor E and Schmitz N: Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Bone Marrow Transplant suppl 3: 581-4, 1998.
53. Hagglund H, Ringden O, Remberger H, Lonnqvist B, Sparrelid E, Tammik L and Kumlien G: Faster neutrophils and platelets engraftment, but no differences in acute GVHD or survival using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplant 22: 131-6, 1998.
54. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl M, Aschan J, Beelen D, Basara N, Kumlien G, Fauser A and Runde V: No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98: 1738-1745, 2001.
55. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N, Holig K, Beelen DW, Hagglund H, Basu O et al: Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 94: 455-64, 1999.
56. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, Lilleby K, Rowley S, Sanders J, Storb R and Buckner CD: Allogeneic peripheral blood stem cell transplantation inpatients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88: 2794-800, 1996.
57. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O et al: Allogeneic bone marrow transplant versus Filgrastim mobilized peripheral blood progenitor cell transplantation in patients with early leukemia: first results of a randomized multicenter trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 995-1003, 1998.
58. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney D, Marr K, Witherspoon R, Bensinger W, Flowers M, Martin P, Storb R, Appelbaum F and Boeckh M: Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97: 3380-3389, 2001.
59. Lapierre V, Oubougar N, Auperin A, Tramalloni D, Tayebi H, Robinet E, Kuentz M, Blaise D, Hartmann O, Herve P and Tiberghien P: Influence of the hematopoietic stem cell source an early immunohematologic reconstitution after allogeneic transplantation. Blood 97: 2580-2586, 2001.
60. Tayebi H, Tiberghien P, Ferrand C, Lienard A, Duperrier A, Cahn J, Lapierre V, Saas P, Kuentz M, Blaise D, Herve P and Robinet E: Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant 27: 167-175, 2001.
61. Rowley SD, Donaldson G, Lilleby K, Bensinger WI and Appelbaum FR: Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 97: 2541-2548, 2001.
62. Gale RP and Champlin RE: How does marrow transplantation cure leukemia? Lancet 2:28-30, 1984.
63. Weiden PL, Sullivan KM, Flournoy N, Storb R and Thomas ED: Antileukemia effect of chronic graft versus host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529-33, 1981.
64. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-62, 1990.
65. Jones RJ, Ambinder RF, Piantadosi S and Santos GW: Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77: 649-653, 1991.
66. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L et al: Graft versus leukemia effect of donor lymphocyte transfusion in marrow grafted patients European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041-50, 1995.
67. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J and Or R: Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23: 1553-1562, 1995.
68. Slavin S. Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interluekin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87: 2195-2004, 1996.
69. Collins RH, Shpilberg O, Drobyski WR et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15: 433-44, 1997.
70. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease: Blood 91: 756-63, 1998.
71. Spitzer TR: Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 5: 215-223, 2000.
72. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S et al: Transplantation-Lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16: 2817-2824, 1998.
73. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr, Rodriguez MA et al: Phase II trail of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10: 790-4, 1992.
74. Baker S and Wagner J: Novel conditioning regimens and nonmyeloablative stem cell transplants. Curr Opin Pediat 14: 17-22, 2002.
75. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B et al: Fludarabine: a new agent with major activity against chronic lymphocytic leukemic. Blood 74: 19-25, 1989.
76. Champlin R, Khouri I and Komblau S: Reinventing bone marrow transplantation. Nonmyeloblative preparative regimen and induction of graft versus malignancy effect. Oncology 13: 621-8, 1999.
77. McSweeney, PA, Niederieser D, Shizuru JA et al: Hematopoetic cell transplantation in older patients with hematologic malignancies: replacing high dose cytotoxic therapy with graft versus tumor effects. Blood 97: 3390-3400, 2001.
78. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, Milpied N, Moreau P, Bordigoni P, Kuentz M, Sadoun A, Cahn J, Socie G, Thomas X, Arnaud P, Raus N, Lhetier V, Pigneux A and Boiron J: Allogeneic hematopoetic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19: 3340-3349, 2001.
79. Chakraverty R, Peggs K, Chopra R, Milligan D, Kottaridis P, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarty S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams C, Yong K, Linch D, Goldstone A and Mackinnon S: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99: 1071-1078, 2002.
80. Giralt SA: Nonmyeloablative stem cell transplantation: lessons from the first generation trials. Leuk Lymph 2: 3-7, 1999.
81. Peggs K and Mackinnon S: Cellular therapy: donor lymphocyte infusion. Hematol 8: 349-354, 2001.
82. Sandmaier BM, McSweeney P, Yu C and Storb R: Non-Myeloablative transplants: preclinical and clinical results. Semin Oncol 27 (Suppl 5): 78-81, 2000.
83. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F and Tricot G: Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20: 1295-1303, 2002.
84. Maloney DG, Sahebi F, Stockerl-Goldstein KE et al: Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 98 (Suppl 1): 434a, 2001.
85. Childs R, Chernoff A, Contentin N, Baheci E, Schrump D, Leitman S et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758, 2000.
86. Van Der Straaten, Fijnheer R, Dekker A, Nieuwenhuis K and Verdonk L: Relationship between graft-versus-host disease and graft-versus-leukemia in partial T cell-depleted bone marrow transplantation. Br J Hematol 114: 31-35, 2001.
87. Chen B, Cui X, Liu C and Chao N: Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99: 3083-3088, 2002.
88. Litvinova E, maury S, Boyer O, Bruel S, Benard L, Boisserie G, Klatzmann D and Cohen JL: Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood 100: 2020-2025, 2002.
89. Mackinnon S, Papadopoulos EB, Carabasi MH et al: Adoptive immunotherapy escalating doses of donor leucocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft versus-host disease. Blood 86: 1261-1268, 1995.
90. Molldrem JJ, Clave E, Jiang YZ et al: Cytotoxic T lymphocytes specific for a non-polymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90: 2529-34, 1997.
91. Molldrem JJ, Dermime S, Parker K et al: Targeted T-cell therapy for human leukemia cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88: 2450-7, 1996.
92. Ohminami H, Yasukawa M and Fujita S: HLA class I- restricted lysis of leukemia cells by a CD8 (+) cytotoxic T- lymphocyte clone specific for WT1 peptide. Blood 95: 286-293, 2000.
93. Oka Y, Elisseva OA, Tsuboi A et al: Human cytotoxic T- lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51: 99-107, 2000.
94. Bocchia M, Korontsvit T, Xu Q et al: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 97: 3587-92, 1996.
95. Van Elsas A, Nijman HW, Van der Minne CE et al: Induction and characterization of cytotoxic T- lymphocytes recognizing a mutated p21ras peptide presented by HLA-A 0201. Int J Cancer 61: 389-96, 1995.
96. Goulmy E: Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157: 125-40, 1997.
97. Warren EH, Gaven M, Greenberg PD and Riddell SR: Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol 5: 429-33, 1998.
98. Childs R, Clave E, Contentin N et al: Engraftment kinetics after non myeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94: 3234-3241, 1999.
99. Rondon G, Giralt S, Huh Y et al: Graft versus- leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18: 669-72, 1996.
100. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N and Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-8, 1996.
101. Chao NJ: Graft- versus- host disease: the viewpoint from the donor T-cell. Biol Bone Marrow Transplant 3: 1-10, 1997.
102. Ruggeri L, Capanni M, Casucci M et al: Role of natural killer alloreactivity in HLA- mismatched hematopoietic stem cell transplantation. Blood 94: 333-9, 1999.
103. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM and Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 87: 2476-85, 1996.
104. Wu CJ, Yang XF, McLaughlin S et al: Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 106: 705-14 2000.
105. McSweeney PA, Niederwieser D, Shizuru JA et al: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400 2001.
106. McSweeney P, Niederwieser D, Shizuru J et al: Outpatient allografting with minimally myelosuppressive immunosuppressive conditioning of low-dose TBI and post grafting cyclosporine and mycophenolate mofetil. Blood 94(suppl 1): 393 a, 1999.
107. Kottaridis PD, Milligan DW, Chopra R et al: In vivo CAMPATH-1H prevents graft-versus-host disease following non myeloablative stem cell transplantation. Blood 96: 2419-2425, 2000.
108. Broxmeyer HE, Gluckman E, Averbach A, Douglas GW, Friedman H, Cooper S, Hangoc G et al: Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning Suppl 1: 76-91, 1990.
109. Emerson SG, Sieff CA, Wang EA, Wong GG, Clark SC and Nathon DG: Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony stimulating activity. J Clin Invest 76: 1286-90, 1985.
110. Christensen RD, Harper TE and Rothstien G: Granulocyte-macrophage progenitor cells in term and preterm neonates. J Pediatr 109: 1047-51, 1986.
111. Broxmeyer HE, Douglas GW, Hangoc G et al: Human umbilical cord blood as a potential source of transplantable hematopoietic stem progenitor cell. Proc Natl Acad Sci USA 86: 3828-32, 1989.
112. Broxmeyer HE, Hangoc G and Cooper S: Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA 89(9): 4109-13, 1992.
113. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H et al: Hematopoietic reconstruction in patient with Fanconi's anemia by means of umbilical cord blood from an HLA identical sibling. N Engl J Med 321: 1174-8, 1989.
114. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE and Gluckman E: Allogeneic sibling umbilical-cord blood transplantation in children with malignant and non-malignant disease. Lancet 346: 214-9, 1995.
115. Kurtzberg J, Laughlin M, Graham MI et al: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335: 157-66, 1996.
116. Wagner JE, Rosenthal J, Sweetman R et al: Successful transplantation of HLA-matched and HLA mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft versus host disease. Blood 88: 795-802, 1996.
117. Gluckman E, Rocha V, Boyer-Chammand A, Locatelli F, Arcese W, Pasquini R, Ortega J et al: Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337: 373-81, 1997.
118. American Academy of Pediatrics Work Group on Cord Blood Banking: Cord blood banking for potential future transplantation: subject review. Pediatrics 104: 1116-8, 1995.
119. Rubinstein P, Carrier C and Scaradavou A: Outcomes among 562 recipient of the placental blood transplants from unrelated donors. N Engl J Med 339: 1565-77, 1998.
120. Sirchia G and Rebulla P: Placental/umbilical cord blood transplantation. Haematologica 84: 738-47, 1999.
121. Rocha V, Wagner J, Sobocinski K, Klein J, Zhang M, Horowitz M and Gluckman E: Graft- versus-host disease in children who have received a cordblood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 342: 1846-54, 2000.
122. Thompson B, Robertson K, Gowan D, Heilman D, Broxmeyer H, Emanuel D, Kotylo P, Brahmi Z and Smith F: Analysis of engraftment, graft-versus-host disease and immune recovery following unrelated donor cord blood transplantation. Blood 96: 2703-2711, 2000.
123. Cairo M and Wagner JE: Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 90: 4665-78, 1997.
124. Laughlin MJ, Barker K, Bambach B, O Koc, Rizzieri D, Wagner J, Gerson S, Lazarus H, Cairo M, Stevens C, Rubinstein P and Kurtzberg J: Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344: 1815-1822, 2001.
125. Chang RS and Seto DS: Perinatal infection by Epstein-Barr virus. Lancet 2: 201, 1979.
126. Stagno S, Pass RF, Cloud G et al: Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus and clinical outcome. JAMA 256: 1904-8, 1986.
127. Fernandex MN, Millian I and Gluckman E: Cord blood transplants. N Engl J Med 340: 1287-8, 1999.
128. Barker J and Wagner J: Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 14: 160-164, 2002.
129. Bertolini F, Battaglia M, de Iulioc et al: Placental blood collection: Effects on newborns. Blood 85: 3361-2, 1995.
130. Sanz GF, Saavedra S, Planelles D, Snenet L, Cervera J, Barragan E, Jimenez C, Larrea L, Martin G, Martinez J, Jarque I, Moscardo F, Plume G, Andreu R, Regadera A, Garcia I, Molla S et al: Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 98: 2332-2338, 2001.
131. Sanz GF, Saavedra S, Jimenez C, Senent L, Cervera J, Panelles D, Bolufer P, Larrea L, Martin G, Martinez J, Jarque I, Moscardo F, Plume G, Andreu R, de
132. Giralt SA and Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 84: 3603-3612, 1994.
133. Giralt S, Escudier S, Kantarjian H et al: Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329: 757-761, 1993.
134. Wagner JE, Vogelsang GB, Zehnbauer BA et al: Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 9: 205-209, 1992.
135. Radich JP, Sanders JE, Buckner CD et al: Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 11: 304-313, 1993.
136. Grigg A, Kannan K, Schwarer AP, Spencer A and Szer J: Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-x for relapsed malignancy after allogeneic bone marrow transplantation. Int Med J 31: 15-22, 2001.
137. Levine JE, Brown T, Penza SL, Beatty P, Cornetta K, Martino R, Drozyski W, Barrett A, Porter D, Giralt S, leis J, Holmes H, Johnson M, Horowitz M and Collins R: Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20: 405-412, 2002.
138. Ballen K, Becker P, Emmons R, Fitzgerald T, Hsieh C, Liu Q, Heyes C, Clark Y, Levy W, Lambert J, Chiafari F, Szymanski I, Rosohansky S, Popovsky M, Stewart M and Quesenberry P: Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100: 442-450, 2002.
139. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, Alessandrino P, Locatelli F, Vernant J, Sierra J, Jouet J, Frassoni F et al: Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 19: 3675-3684, 2001.
140. Nemunaitis J, Rabinowe SN, Singer JW et al: Recombinant granulocyte-macrophage colony factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324: 1773-1778, 1991.
141. Gorin N, Cioffier B, Hayat M et al: Recombinant human granulocyte-macrophage colony-stimulating factor after high dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double blind placebo controlled trial. Blood 80: 1149-1157, 1992.
142. Taylor KM, Jagannath S, Spitzer G et al: Recombinant human granulocyte-colony stimulating factor hastens granulocyte recovery after high dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7: 1791-1799, 1989.
143. Schriber JR, Negrin RS, Chao NJ et al: The efficacy of granulocyte colony stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged marrow. Leukemia 7: 1491-1495, 1993.
144. Nemunaitis, Buckner CD, Appelbaum FR et al: Phase I/II trial of recombinant human granulocyte-macrophage colony stimulating factor following allogeneic bone marrow transplantation. Blood 77: 2065-2068, 1991.
145. Powles R, Smith C, Milan S et al: Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: double blind placebo controlled trial. Lancet 336: 1417-1420, 1990.
146. DeWitte T, Gratwohl A, Van Der Lely N et al: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophils and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 79: 1359-1365, 1992.
147. Nemunaitis J, Rosenfeld C, Ash R et al: Phase III double blind trial of rh GM-CSF following allogeneic bone marrow transplantation (Abstract). Blood 82: 1128a, 1993.
148. Anasetti C, Anderson G, Appelbaum FR et al: Phase III study of rh GM-CSF in allogeneic marrow transplantation from unrelated donors (Abstract). Blood 82: 1799a, 1993.
149. Masaoka T, Takaku F, Kato S et al: Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol 17: 1047-1050, 1989.
150. Linch DC, Scarffe H, Proctor S et al: Randomized vehicle controlled dose finding study of glycocylated recombinant human granulocyte colony stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11: 307-311, 1993.
151. Pryepiroka D, Smith TL, Folloder J, Anderlini P, Chan K, Koerbling M, Lichtinger B, Norfleet F and Champlin R: Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 97: 3405-3410, 2001.
152. Bishop Mr, Tarantolo SR, Geller RB, Lynch J, Bierman P, Pavletic S, Vose J, Kruse S, Dix S, Morris M, Armitage J and Kessinger A: A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96: 80-85, 2000.
153. Tayebi H, Lapievre V, Saas P, Lienard A, Sutton L, Milpied N, Attal M, Cahn J, Kuentz M, Blaise D, Herve P, Tiberghien P and Robinet E: Enhanced activation of B cells in a granulocyte colony-stimulating factor- mobilized peripheral blood stem cell graft. Br J Haematol 114: 698-700, 2001.